Current treatment options for elderly patients with multiple myeloma

Clinical impact of novel agents

Sumit Madan, Shaji K Kumar

Research output: Contribution to journalArticle

Abstract

Multiple myeloma is a plasma cell malignancy that typically affects older individuals, with a median age of presentation being 67-70 years. The treatment paradigms for myeloma have changed dramatically in the past decade as a result of the introduction of several new drugs, as well as more widespread use of high-dose chemotherapy and stem cell transplantation. However, transplant is not an option for a significant proportion of the older patients, owing to either age or comorbidities. In recent years, judicious combination of the new drugs with existing therapies has led to improved outcomes in this group of patients. This article serves to highlight the modern treatment strategies incorporating novel agents, role of maintenance therapy and feasibility of stem cell transplantation in elderly patients with multiple myeloma.

Original languageEnglish (US)
Pages (from-to)415-429
Number of pages15
JournalTherapy
Volume8
Issue number4
DOIs
StatePublished - Jul 2011

Fingerprint

Multiple Myeloma
Stem Cell Transplantation
Drug Combinations
Therapeutics
Plasma Cells
Comorbidity
Transplants
Drug Therapy
Pharmaceutical Preparations
Neoplasms

Keywords

  • elderly
  • immunomodulatory agent
  • melphalan
  • monoclonal gammopathy
  • myeloma
  • prednisone
  • proteasome inhibitors
  • stem cell transplant

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Medicine(all)

Cite this

Current treatment options for elderly patients with multiple myeloma : Clinical impact of novel agents. / Madan, Sumit; Kumar, Shaji K.

In: Therapy, Vol. 8, No. 4, 07.2011, p. 415-429.

Research output: Contribution to journalArticle

@article{bfe891c5339e4e01959443f6d90fe37d,
title = "Current treatment options for elderly patients with multiple myeloma: Clinical impact of novel agents",
abstract = "Multiple myeloma is a plasma cell malignancy that typically affects older individuals, with a median age of presentation being 67-70 years. The treatment paradigms for myeloma have changed dramatically in the past decade as a result of the introduction of several new drugs, as well as more widespread use of high-dose chemotherapy and stem cell transplantation. However, transplant is not an option for a significant proportion of the older patients, owing to either age or comorbidities. In recent years, judicious combination of the new drugs with existing therapies has led to improved outcomes in this group of patients. This article serves to highlight the modern treatment strategies incorporating novel agents, role of maintenance therapy and feasibility of stem cell transplantation in elderly patients with multiple myeloma.",
keywords = "elderly, immunomodulatory agent, melphalan, monoclonal gammopathy, myeloma, prednisone, proteasome inhibitors, stem cell transplant",
author = "Sumit Madan and Kumar, {Shaji K}",
year = "2011",
month = "7",
doi = "10.2217/thy.11.39",
language = "English (US)",
volume = "8",
pages = "415--429",
journal = "Therapy",
issn = "2044-9038",
publisher = "Future Medicine Ltd.",
number = "4",

}

TY - JOUR

T1 - Current treatment options for elderly patients with multiple myeloma

T2 - Clinical impact of novel agents

AU - Madan, Sumit

AU - Kumar, Shaji K

PY - 2011/7

Y1 - 2011/7

N2 - Multiple myeloma is a plasma cell malignancy that typically affects older individuals, with a median age of presentation being 67-70 years. The treatment paradigms for myeloma have changed dramatically in the past decade as a result of the introduction of several new drugs, as well as more widespread use of high-dose chemotherapy and stem cell transplantation. However, transplant is not an option for a significant proportion of the older patients, owing to either age or comorbidities. In recent years, judicious combination of the new drugs with existing therapies has led to improved outcomes in this group of patients. This article serves to highlight the modern treatment strategies incorporating novel agents, role of maintenance therapy and feasibility of stem cell transplantation in elderly patients with multiple myeloma.

AB - Multiple myeloma is a plasma cell malignancy that typically affects older individuals, with a median age of presentation being 67-70 years. The treatment paradigms for myeloma have changed dramatically in the past decade as a result of the introduction of several new drugs, as well as more widespread use of high-dose chemotherapy and stem cell transplantation. However, transplant is not an option for a significant proportion of the older patients, owing to either age or comorbidities. In recent years, judicious combination of the new drugs with existing therapies has led to improved outcomes in this group of patients. This article serves to highlight the modern treatment strategies incorporating novel agents, role of maintenance therapy and feasibility of stem cell transplantation in elderly patients with multiple myeloma.

KW - elderly

KW - immunomodulatory agent

KW - melphalan

KW - monoclonal gammopathy

KW - myeloma

KW - prednisone

KW - proteasome inhibitors

KW - stem cell transplant

UR - http://www.scopus.com/inward/record.url?scp=79961047778&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79961047778&partnerID=8YFLogxK

U2 - 10.2217/thy.11.39

DO - 10.2217/thy.11.39

M3 - Article

VL - 8

SP - 415

EP - 429

JO - Therapy

JF - Therapy

SN - 2044-9038

IS - 4

ER -